DocMorris AG (OTCPK:ZRSEF)

$ 39.03 -3.4708 (-8.17%) Market Cap: 505.27 Mil Enterprise Value: 785.97 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 62/100

Half Year 2024 DocMorris AG Earnings Call Transcript
Aug 20, 2024

$53.13

Earnings
Full Year 2023 DocMorris AG Earnings Call Transcript
Mar 21, 2024

$88.6

Earnings
Half Year 2023 Zur Rose Group AG Earnings Call Transcript
Aug 17, 2023

$64.31 (+6.09%)

Earnings
Full Year 2022 Zur Rose Group AG Earnings Call Transcript
Mar 23, 2023

$27.06

Earnings
Half Year 2022 Zur Rose Group AG Earnings Call Transcript
Aug 18, 2022

$63.15

Earnings
Full Year 2021 Zur Rose Group AG Earnings Call Transcript
Mar 24, 2022

$118.04 (-24.33%)

Earnings
Half Year 2021 Zur Rose Group AG Earnings Call Transcript
Aug 18, 2021

$380

Earnings
Zur Rose Group AG Capital Markets Day (Virtual) Transcript
Jun 16, 2021
Full Year 2020 Zur Rose Group AG Earnings Call Transcript
Mar 18, 2021

$383.69 (-29.86%)

Earnings
Half Year 2020 Zur Rose Group AG Earnings Call Transcript
Aug 19, 2020

$307

Earnings
Full Year 2019 Zur Rose Group AG Earnings Call Transcript
Mar 19, 2020

$94.27

Earnings

Half Year 2022 Zur Rose Group AG Earnings Call Transcript

Aug 18, 2022 / 09:00AM GMT

Release Date Price: $63.15

Transcript

Operator

Good day, and welcome to the Zur Rose Group AG 2022 Half Year Results Conference Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Walter Hess. Please go ahead, sir.

Walter Hess

Zur Rose Group AG - CEO & Member of Executive Board

Good morning, and welcome to everybody. Marcel and I, we are very happy to present to you the half year results today. The world is facing many turbulences at the moment, resulting in uncertainties in the markets. Whereas our business with pharmaceuticals is hardly impacted by all of that. On the contrary, our key messages for you today are that we have set all our key priority on achieving EBITDA breakeven already in 2023. And as a result, there is no additional cash needed for operational business.

Our highly efficient distribution center in Heerlen is live. And the medpex brands integration has started. And with the rollout of the eRx in Germany, the digitalization of a EUR 50 billion market with prescribed medication will take off now.

So let's

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.